Updating the Surgical Management of Peritoneal Carcinomatosis in Patients with Neuroendocrine Tumors

Well-differentiated digestive neuroendocrine tumors (NET) are a heterogeneous group of neoplasms usually associated with slow growth but a high rate of metastases, including peritoneal carcinomatosis (PC). Herein, we aimed to comprehensively review the current knowledge of PC in terms of implications for the management and prognosis of patients with NET, including the latest studies and expert statements. NET-derived PC concerns about 17% of NET patients and up to 30% of those with small intestine primary NET. It has an independent pejorative prognostic impact. The extent of PC in NET patients and its severity can be expressed by analogy to other malignancies. However, it must be placed in the context of NET disorders, which usually vary from other PCrelated malignancies. Recently, a gravity PC score was proposed by a consensus European Neuroendocrine Tumor Society (ENETS) expert group, but it requires validation. In adReceived: September 23, 2014 Accepted after revision: December 31, 2014 Published online: January 9, 2015 Reza Kianmanesh Department of General, Digestive and Endocrine Surgery Robert-Debré University Hospital 125, avenue du Général Koenig, FR–51100 Reims Cedex (France) E-Mail rkianmanesh @ chu-reims.fr © 2015 S. Karger AG, Basel 0028–3835/15/1012–0105$39.50/0